Login to Your Account



Disappointing Data

Peramivir Miss Drops BioCryst; Catalyst Falls on Cocaine Trial

By Jennifer Boggs
Managing Editor

Friday, November 9, 2012
Disappointing clinical data clobbered shares of two biotech firms Thursday: BioCryst Pharmaceuticals Inc. fell 40.4 percent on news that a Phase III trial of influenza candidate peramivir would be halted for futility, while Catalyst Pharmaceutical Partners lost nearly two-thirds of its value after reporting a Phase IIb miss for cocaine-dependence candidate CPP-109.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription